Viatris Beats Q1 Earnings Estimates on China Strength

Viatris reported Q1 earnings that surpassed estimates, driven by strong sales in China. The company's branded drug sales were a key factor in the increased revenue. Despite a 3% decline in shares, Viatris reaffirmed its guidance for 2026. The company's Q1 earnings beat was powered by significant growth in Greater China.

Viatris delivered a strong Q1 2026, with earnings per share (EPS) beating analyst estimates. The increase in revenue was primarily driven by strong performance in Greater China, where the company's branded drugs showed significant growth.

The strong Q1 results come as the first quarter is historically the weakest of the year for the drugmaker, but analysts will now be watching closely for the rest of the year. Despite the solid Q1 showing, Viatris shares fell 3% in the wake of the report, although this reaction could be short-lived as the company reaffirmed its full-year guidance.

Going forward, Viatris appears well positioned for near-term growth, driven by its ongoing momentum in Greater China and cost-cutting efforts aimed at supporting the stock price.

Related Stocks

VTRS